RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS, INC. (RLMD): 3 pipeline candidates · 2 upcoming catalysts · ~44 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
44.4 months
D/E 0.08 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~12d
N/A
A transparent, data-derived signal for RELMADA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$676.5M
Cash
$9.8M
Quarterly Burn
$15.1M
Runway
44.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ndv-01 | Phase 3 |
| rel-1017 | Phase 3 |
| sepranolone | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
101
Total value held
$549.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 22,127,724 | $153.8M |
| vanguard capital management llc | 6,153,140 | $42.8M |
| adage capital partners gp, l.l.c. | 4,763,158 | $33.2M |
| orbimed advisors llc | 4,715,864 | $32.8M |
| marshall wace, llp | 4,481,606 | $31.2M |
| millennium management llc | 3,907,265 | $27.2M |
| ra capital management, l.p. | 2,947,369 | $20.5M |
| ikarian capital, llc | 2,688,359 | $18.7M |
| driehaus capital management llc | 2,132,053 | $14.8M |
| polar capital holdings plc | 1,414,621 | $9.8M |
Showing top 10 of 101 institutional holders of RELMADA THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in RELMADA THERAPEUTICS, INC.'s pipeline?
RELMADA THERAPEUTICS, INC. (RLMD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RELMADA THERAPEUTICS, INC.'s lead drug candidate?
RELMADA THERAPEUTICS, INC.'s most advanced tracked candidate is ndv-01 (Phase 3) for Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive).
What is RELMADA THERAPEUTICS, INC.'s next catalyst?
RELMADA THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Start event — "Phase 3 Start: A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Mu" — expected June 30, 2026.
What is RELMADA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RELMADA THERAPEUTICS, INC. has approximately 44.4 months of cash runway.
What is RELMADA THERAPEUTICS, INC.'s market capitalization?
RELMADA THERAPEUTICS, INC.'s market capitalization is approximately $676.5M.
Get the full picture on RELMADA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.